The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART).
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 2254131.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Continuous, hyperfractionated, accelerated radiotherapy (CHART) was devised to give the maximum chance of improving clinical radiotherapy and was based upon available radiobiological evidence. A pilot study, begun in 1985, has now included 210 patients. When comparison is made with previously treated cases, improved results have been seen in the two main groups included, that is, advanced head and neck and bronchial carcinomas. Multi-center randomized controlled clinical trials are planned.
Medical subject headings
- Neoplasms
- Radiotherapy